Exagen Inc.
XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lā¦ read more
Healthcare
Diagnostics & Research
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.17
Price+2.49%
$0.15
1Y
Price
Market Cap
$139.831m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-30.8%
EBITDA Margin-41.1%
Net Profit Margin+15.5%
Free Cash Flow Margin-30.8%
EBITDA Margin-41.1%
Net Profit Margin+15.5%
Free Cash Flow MarginRevenue
$63.599m
+14.3%
1y CAGR+11.8%
3y CAGR+7.5%
5y CAGREarnings
-$19.039m
-26.0%
1y CAGR+20.1%
3y CAGR-4.1%
5y CAGREPS
-$0.92
-10.8%
1y CAGR+26.3%
3y CAGR+3.5%
5y CAGRBook Value
$18.138m
$62.823m
Assets$44.685m
Liabilities$28.167m
DebtDebt to Assets
44.8%
-2.1x
Debt to EBITDAFree Cash Flow
-$10.992m
+20.3%
1y CAGR+29.4%
3y CAGR+6.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company